Tricyclic HIV integrase inhibitors: VI. SAR studies of ‘benzyl flipped’ C3-substituted pyrroloquinolines
摘要:
A series of C3 halobenzyl-substituted tricyclic HIV integrase inhibitors was prepared. Improvement in cell-based inhibitor potency was observed in comparison to previously disclosed tricyclic pyrroloquinolines carrying the 'halobenzyl tail' at the lactam nitrogen. Animal PK for several of the C3-substituted inhibitors was examined, with a dihaloaryl analog achieving good balance in protein-shifted EC50 and t(1/2) in animal PK studies. (C) 2008 Elsevier Ltd. All rights reserved.
[EN] Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. [FR] L'invention concerne des composés tricycliques, des intermédiaires protégés de ceux-ci, ainsi que des méthodes d'inhibition de l'intégrase du VIH.
Integrase inhibitors
申请人:Cai R. Zhenhong
公开号:US20080058315A1
公开(公告)日:2008-03-06
Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
三环化合物,其受保护的中间体,以及用于抑制HIV整合酶的方法被披露。
Tricyclic HIV integrase inhibitors: VI. SAR studies of ‘benzyl flipped’ C3-substituted pyrroloquinolines
作者:Sammy Metobo、Michael Mish、Haolun Jin、Salman Jabri、Rachael Lansdown、Xiaowu Chen、Manuel Tsiang、Matthew Wright、Choung U. Kim
DOI:10.1016/j.bmcl.2008.12.079
日期:2009.2
A series of C3 halobenzyl-substituted tricyclic HIV integrase inhibitors was prepared. Improvement in cell-based inhibitor potency was observed in comparison to previously disclosed tricyclic pyrroloquinolines carrying the 'halobenzyl tail' at the lactam nitrogen. Animal PK for several of the C3-substituted inhibitors was examined, with a dihaloaryl analog achieving good balance in protein-shifted EC50 and t(1/2) in animal PK studies. (C) 2008 Elsevier Ltd. All rights reserved.